Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15111335 | 0.83 | LOXL2 (0.43) | LOXL2PTGER4GAAMAPTCD274 | |
| SCHEMBL660561 | 0.79 | LOXL2 (0.39) | LOXL2PTGER4MAPTCD274 | |
| SCHEMBL660560 | 0.79 | LOXL2 (0.39) | LOXL2PTGER4MAPTCD274 | |
| SCHEMBL4415047 | 0.77 | CYP2A6 (0.35) | LOXL2 | |
| SCHEMBL16269988 | 0.75 | LOXL2 (0.42) | LOXL2PTGER4MAPTCD274 | |
| SCHEMBL967563 | 0.72 | CYP2A6 (0.39) | — | |
| SCHEMBL17256208 | 0.70 | LOXL2 (0.41) | LOXL2PTGER4MAPTCD274 | |
| SCHEMBL17256209 | 0.70 | LOXL2 (0.41) | LOXL2PTGER4MAPTCD274 | |
| SCHEMBL4504370 | 0.69 | SLC6A2 (0.31) | — | |
| SCHEMBL13143573 | 0.66 | LOXL2 (0.61) | LOXL2GAAMAPTCD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429615-B2 | Cyclohexyl prostaglandin analogs as EP4-receptor agonists | ALLERGAN, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060247215-A1 | Cyclohexyl prostaglandin analogs as rp4-receptor agonists | OLD DAVID W | 2006-11-02 | — | — | US | disclosed |
| US-7015243-B2 | Cyclohexyl prostaglandin analogs as EP4-receptor agonists | ALLERGAN, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050049227-A1 | Cyclohexyl prostaglandin analogs as EP4-receptor agonists | ALLERGAN, INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247215-A1 | Cyclohexyl prostaglandin analogs as rp4-receptor agonists | PTGER4, PTGER1, PTGER3 | LOXL2 1138/4885PTGER4 1/4885GAA 4833/4885 |
| US-20050049227-A1 | Cyclohexyl prostaglandin analogs as EP4-receptor agonists | PTGER4, PTGER1, PTGIR | LOXL2 1068/4885PTGER4 1/4885GAA 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.